[1]范永增,袁耿彪.靶向性纳米药物对肿瘤的应用研究[J].国际放射医学核医学杂志,2010,34(1):16-19.[doi:10.3760/cma.j.issn.1673-4114.2010.01.004]
　FAN Yong-zeng,YUAN Geng-biao.Application of targeting nano-drug for neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):16-19.[doi:10.3760/cma.j.issn.1673-4114.2010.01.004]
点击复制

靶向性纳米药物对肿瘤的应用研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
34
期数:
2010年第1期
页码:
16-19
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Application of targeting nano-drug for neoplasms
作者:
范永增;  袁耿彪
400010, 重庆医科大学附属第二医院核医学科
Author(s):
FAN Yong-zeng;  YUAN Geng-biao
Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
关键词:
抗肿瘤药物; 药物设计; 纳米医学
Keywords:
Antineoplastic agent; Drug design; Nanomedicine
DOI:
10.3760/cma.j.issn.1673-4114.2010.01.004
摘要:
随着纳米科学与技术的兴起,纳米药物在生物医药领域中的应用日益受到重视。目前关注的热点是在纳米药物的基础上,通过物理、化学及生物合成的方法,连接能够结合肿瘤细胞的特异性免疫活性物质,使其成为具有靶向性的纳米药物,用于肿瘤的诊断和治疗。该文着重评述了纳米药物的概念及靶向性纳米药物的研究进展。
Abstract:
With the rise of nano science and technology, more and more researchers will take attention to application of nano-drugs in the biomedical field. The current focus of concern is that a target of nano-drugs linked specificity immunoreactive substances combine to tumor cells for diagnosis and treatment by physical, chemical and biological synthesis methods in based on nano-drugs. This paper mainly reviewed the concept of nano-drug and development of nano-drug targeting research.

参考文献/References:

[1] Whitesides GM.The ‘right’ size in nanobiotechnology.Nat Biotechnol,2003,21(10):1161-1165.
[2] Liu Y,Miyoshi H,Nakamura M.Nanomedicine for drug delivery and imaging:a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles.Int J Cancer,2007,120(12):2527-2537.
[3] Jain KK.Nanomedicine:application of nanobiotechnology in medical practice.Med Princ Pract,2008,17(2):89-101.
[4] Farokhzad OC,Cheng J,Teply BA,et al.Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci USA,2006,103(16):6315-6320.
[5] Singh S,Ray SS.Polylactide based nanostructured biomaterials and their applications J Nanosci Nanotechnol,2007,7(8):2596-2615.
[6] Kogan MJ,Olmedol,HostaL,et al.Peptidesandmetallicnanoparficles for biomedical applications.Nanomedicine lond,2007,2(3):287-306.
[7] Wollina U,Dummer R,Brockmeyer NH,et al.Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.Cancer,2003,98(5):993-1001.
[8] Park JW,Hong K,Kirpotin DB,et al.Anti-HER2 immunoliposomes:enhanced efficacy attributable to targeted delivery.Clin Cancer Res,2002,8(4):1172-1181.
[9] Farokhzad OC,Cheng J,Teply BA,et al.Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci USA,2006.103(16):6315-6320.
[10] Blagbrough IS,Zara C.Animal models for target diseases in gene therapy-using DNA and siRNA delivery strategies.Pharm Res,2009,26(1):1-18.
[11] Schmieder AH,Winter PM,Caruthers SD,et al.Molecular MR imaging of melanoma an giogenesis with alphanubeta-targeted paramagnetic nanoparticles.Magn Reson Med,2005,53(3):621-627.
[12] Tkachenko AG,Xie H,Liu Y,et al.Cellular trajectories of peptidemodified gold particle complexes:comparison of nuclear localization signals and peptide transduction domains.Bioconjugate Chem,2004,15(3):482-490.
[13] Hood JD,Bednarski M,Frausto R,etal.Tumorregression by targeted gene delivery to the neovasculature.Science,2002,296(5577):2404-2407.
[14] Lee JH,Lee K,Moon SH,et al.All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery.Angew Chem Int Ed Engl,2009,48(23):4174-4179.
[15] Bodei L,Cremonesi M,Zoboli S,et al.Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:a phase I study.Eur J Nucl Med Mol Imaging,2003,30(2):207-216.
[16] Bodei L,Cremonesi M,Grana C,et al.Receptor radionuclide therapy with 90Y-[DOTA] 0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.Eur J Nucl Med Mol Imaging,2004,31(7):1038-1046.
[17] Valkema R,Pauwels S,Kvols LK,et al.Survival and response after peptide receptor radionuclide therapy with[90Y-DOTA0,Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.Semin Nucl Med,2006,36(2):147-156.
[18] 熊平,郭萍,袁亚莉,等.顺磁纳米铁核素的研制及性能分析.中国生物医学工程学报,2005,24(2):154-156.
[19] Hamoudeh M,Al Faraj A,Canet-SoulasE,et al.Elaboration of PLLA-based superparamagnetic nanoparticles:characterization,magnetic be-haviour study and in vitro relaxivity evaluation.Int J Pharm,2007,338(1-2):248-257.

相似文献/References:

[1]周雪,乔晋萍,孔爱英,等.受体结合实验及其在放射性显像剂研究中的应用进展[J].国际放射医学核医学杂志,2010,34(6):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
　ZHOU Xue,QIAO Jin-ping,KONG Ai-ying,et al.Progress on the application of ligand receptor binding assays in radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
[2]方圣伟,奚望,张宏.分子核医学的发展和应用前景[J].国际放射医学核医学杂志,2009,33(6):321.[doi:10.3760/cma.j.issn.1673-4114.2009.06.001]
　FANG Sheng-wei,XI Wang,ZHANG Hong.The developments and applications of molecular nuclear medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):321.[doi:10.3760/cma.j.issn.1673-4114.2009.06.001]
[3]张锦明,田嘉禾,刘伯里.影响PET放射性药物11C甲基化的因素[J].国际放射医学核医学杂志,2006,30(5):271.
　ZHANG Jing-ming,TIAN Jia-he,LIU Bo-li.Influence factor on 11C methylation in PET radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):271.

备注/Memo

备注/Memo:
收稿日期:2009-10-12。
基金项目:重庆市科委自然科学基金(2007BB5310)
通讯作者:哀耿彪,E-mail:yuan_gb@126.com
更新日期/Last Update: 1900-01-01